Griffin, John P. - In: PharmacoEconomics 14 (1998) 3, pp. 241-250
New medicines can be cost effective, and the under use of many therapeutic advances has been a cause for concern. Equally, the introduction of certain expensive products onto the market prematurely where adequate clinical studies have not been conducted equally represents an unsatisfactory...